Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 17/20 | 0.77 |
| ▸ | RPS6KA1 | Q15418 | 13/20 | 0.77 |
| ▸ | RPS6KA5 | O75582 | 7/20 | 0.77 |
| ▸ | ROCK1 | Q13464 | 14/20 | 0.68 |
| ▸ | AKT2 | P31751 | 7/20 | 0.59 |
| ▸ | AKT3 | Q9Y243 | 2/20 | 0.59 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.50 |
| ▸ | GSK3B | P49841 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4068592 | 0.97 | AKT1 (0.81) | AKT1RPS6KA1RPS6KA5ROCK1AKT2 | |
| Trifluoroacetic Acid SCHEMBL5066192 | 0.93 | AKT1 (0.69) | AKT1RPS6KA1RPS6KA5ROCK1AKT2 | |
| Trifluoroacetic Acid SCHEMBL5067615 | 0.90 | AKT1 (0.72) | AKT1RPS6KA1RPS6KA5ROCK1AKT2 | |
| SCHEMBL5058523 | 0.90 | AKT1 (0.94) | AKT1RPS6KA1RPS6KA5ROCK1AKT2 | |
| SCHEMBL5066217 | 0.89 | AKT1 (0.93) | AKT1RPS6KA1RPS6KA5ROCK1AKT2 | |
| SCHEMBL4068279 | 0.87 | AKT1 (0.83) | AKT1RPS6KA1RPS6KA5ROCK1AKT2 | |
| SCHEMBL4248428 | 0.87 | AKT1 (1.00) | AKT1RPS6KA1RPS6KA5ROCK1AKT2 | |
| SCHEMBL5063634 | 0.84 | AKT1 (0.91) | AKT1RPS6KA1RPS6KA5ROCK1AKT2 | |
| SCHEMBL5067604 | 0.83 | RPS6KA5 (0.56) | AKT1RPS6KA1RPS6KA5ROCK1SLC2A1 | |
| Trifluoroacetic Acid SCHEMBL5062549 | 0.83 | AKT1 (0.64) | AKT1RPS6KA1RPS6KA5ROCK1AKT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1653961-A4 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORP (US) | 2009-04-01 | — | — | EP | claimed |
| US-20080255143-A1 | Inhibitors of Akt Activity | SMITHKLINE BEECHAM CORPORATION (PA) | 2008-10-16 | — | — | US | claimed |
| EP-1653961-A1 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2006-05-10 | — | — | EP | claimed |
| WO-2005011700-A1 | INHIBITORS OF Akt ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2005-02-10 | — | — | WO | claimed |
| US-20080255143-A1 | Inhibitors of Akt Activity | SMITHKLINE BEECHAM CORPORATION (PA) | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255143-A1 | Inhibitors of Akt Activity | PI4KB, PIK3CA, AKT2 | AKT1 5/4885RPS6KA1 127/4885RPS6KA5 156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.